688767 博拓生物
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.3617.0274.28433.144--
总资产报酬率 ROA (%)0.3396.5433.99929.852--
投入资产回报率 ROIC (%)0.3606.9424.18932.497--

边际利润分析
销售毛利率 (%)46.17552.84250.33153.46161.831
营业利润率 (%)10.48934.57426.42448.09453.162
息税前利润/营业总收入 (%)1.11524.1056.81239.66353.371
净利润/营业总收入 (%)8.70729.81323.81840.68945.969

收益指标分析
经营活动净收益/利润总额(%)62.891101.594123.529105.381100.559
价值变动净收益/利润总额(%)17.7773.6162.9171.6470.110
营业外收支净额/利润总额(%)2.6240.776-0.817-1.3800.217

偿债能力分析
流动比率 (X)16.73910.51413.96613.066--
速动比率 (X)16.04810.10313.30112.275--
资产负债率 (%)4.6987.2936.1576.879--
带息债务/全部投入资本 (%)0.135-0.1381.6831.666--
股东权益/带息债务 (%)73,854.146-72,239.2305,818.7475,859.963--
股东权益/负债合计 (%)2,027.0161,269.5761,520.7341,353.085--
利息保障倍数 (X)-0.115-2.245-0.351-5.100569.766

营运能力分析
应收账款周转天数 (天)84.25551.27441.00417.5850.000
存货周转天数 (天)141.281117.856192.23956.3330.000